Oragenics Inc (OGEN) stock has fallen 14.89% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With OGEN Stock Today?
Oragenics Inc (OGEN) stock has fallen -24.81% while the S&P 500 is up 0.39% as of 2:10 PM on Friday, Nov 20. OGEN is down -$0.13 from the previous closing price of $0.53 on volume of 21,961,056 shares. Over the past year the S&P 500 has risen 15.23% while OGEN is down -18.37%. OGEN lost -$0.50 per share in the over the last 12 months.
To screen for more stocks like Oragenics Inc click here.
More About Oragenics Inc
Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and have other product candidates, including SMaRT Replacement Therapy positioned for out-licensing or partnering.
Click Here to get the full Stock Score Report on Oragenics Inc (OGEN) Stock.
